Eli Lilly’s Foundayo Meets Cardiovascular Safety Endpoint in Type 2 Diabetes Trial

The significance here is not the glycemic or weight advantage — oral GLP-1s were already expected to compete on that front — but the cardiovascular and mortality data, which is the evidentiary bar payers and guidelines typically demand before a diabetes therapy displaces entrenched injectable insulin. A non-inferiority endpoint met with a favourable MACE-4 separation, plus markedly lower cardiovascular and all-cause death signals in prespecified analyses, shifts the commercial conversation from convenience toward outcomes. Whether these prespecified mortality findings hold up under fuller scrutiny, and how regulators and payers treat an oral option against established injectables, is the open question.